A Randomized Phase IIB Evaluation of Weekly Paclitaxel (NSC #673089) Plus Pazopanib (NSC #737754) Versus Weekly Paclitaxel Plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Pazopanib (Primary) ; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 31 May 2018 Status changed from active, no longer recruiting to completed.
- 22 Dec 2017 Planned primary completion date changed from 1 May 2017 to 31 Jul 2019.
- 10 Jun 2017 Biomarkers information updated